CLINICAL TRIALS PROFILE FOR EPINEPHRINE
✉ Email this page to a colleague
All Clinical Trials for Epinephrine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000290 ↗ | Stress Hormones and Human Cocaine Use - 7 | Completed | University of Minnesota | Phase 1 | 1997-05-01 | The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration. |
| NCT00000290 ↗ | Stress Hormones and Human Cocaine Use - 7 | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 1 | 1997-05-01 | The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration. |
| NCT00000290 ↗ | Stress Hormones and Human Cocaine Use - 7 | Completed | National Institute on Drug Abuse (NIDA) | Phase 1 | 1997-05-01 | The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration. |
| NCT00001724 ↗ | Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 | 1997-11-01 | This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery. Flurbiprofen is approved by the Food and Drug Administration for treatment of arthritis pain. Patients 16 years of age and older requiring third molar (wisdom tooth) extraction may be eligible for this study. Patients will undergo oral surgery to remove two lower third molar teeth. Before surgery, they will be given a local anesthetic (lidocaine with epinephrine) injected in the mouth and a sedative (Versed) infused through a catheter (thin plastic tube) placed in an arm vein. At the time of surgery, patients will also be given flurbiprofen or a placebo formulation (look-alike substance with no active ingredient) directly into the extraction site and a capsule that also may contain flurbiprofen or placebo. One in seven patients will receive only placebo. All patients will fill out pain questionnaires and stay in the clinic for up to 6 hours for observation of bleeding and medication side effects. Patients who do not have satisfactory pain relief from the test medicine after surgery may request a standard pain reliever. A small blood sample will be collected during surgery and at 15 minutes, one-half hour and 1, 2, 3, 4, 5, 6, 24 and 48 hours after surgery to measure flurbiprofen blood levels. A total of 33 ml (about 2 tablespoons) of blood will be drawn for these tests. Samples collected on the day of surgery will be drawn from the catheter used to administer the sedative; the 24- and 48-hour samples will be taken by needle from an arm or hand vein. Urine samples will also be collected between 4 and 6 hours after surgery and again at 24 and 48 hours after surgery. |
| NCT00002659 ↗ | Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer | Unknown status | Matrix Pharmaceutical | Phase 3 | 1995-05-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if treatment with cisplatin plus epinephrine is effective for head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of cisplatin plus epinephrine in injectable gel form in treating patients who have recurrent or refractory head and neck cancer. |
| NCT00003044 ↗ | Chemotherapy in Treating Patients With Liver Cancer | Unknown status | Matrix Pharmaceutical | Phase 2 | 1996-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin and epinephrine administered directly into the tumor in treating patients who have primary liver cancer that cannot be removed during surgery. |
| NCT00004847 ↗ | Diagnosis of Pheochromocytoma | Recruiting | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 | 2000-03-22 | The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often difficult to detect with current methods. Pheochromocytomas release chemicals called catecholamines, causing high blood pressure. Undetected, the tumors can lead to severe medical consequences, including stroke, heart attack and sudden death, in situations that would normally pose little or no risk, such as surgery, general anesthesia or childbirth. Patients with pheochromocytoma may be eligible for this study. Candidates will be screened with a medical history and physical examination, electrocardiogram, and blood and urine tests. Study participants will undergo blood, urine, and imaging tests, described below, to detect pheochromocytoma. If a tumor is found, the patient will be offered surgery. If surgery is not feasible (for example, if there are multiple tumors that cannot be removed), evaluations will continue in follow-up visits. If the tumor cannot be found, the patient will be offered medical treatment and efforts to detect the tumor will continue. Main diagnostic and research tests may include the following: 1. Blood tests - mainly measurements of plasma or urine catecholamines and metanephrines as well as methoxytyramine. If necessary the clonidine suppression test can be carried out. 2. Standard imaging tests - Non-investigational imaging tests include computed tomography (CT), magnetic resonance imaging (MRI), sonography, and 123I-MIBG scintigraphy and FDG (positron emission tomography) PET/CT. These scans may be done before and/or after surgical removal of pheochromocytoma. 3. Research PET scanning is done using an injection of radioactive compounds. Patients may undergo 18F-FDOPA, 18F-DA, as well as 68Ga-DOTATATE PET/CT . Each scan takes up to about 2 hours. 4. Genetic testing - A small blood sample is collected for DNA analysis and other analyses. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Epinephrine
Condition Name
Clinical Trial Locations for Epinephrine
Trials by Country
Clinical Trial Progress for Epinephrine
Clinical Trial Phase
Clinical Trial Sponsors for Epinephrine
Sponsor Name
